Evan S. Dellon

Jul 25, 2024 | healio.com | Richard Gawel |Kristen Dowd |Evan S. Dellon

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Index of Severity for Eosinophilic Esophagitis scores clustered under 10 and at 15 and higher. Children had more severe symptoms and complications scores and adults had more severe fibrostenotic features.

Feb 2, 2024 | healio.com | Richard Gawel |Evan S. Dellon |Kristen Dowd

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Children with eosinophilic esophagitis currently rely on elimination diets. The safety profile for this age group was consistent with the safety profiles of older patients.

Feb 27, 2023 | thelancet.com | Kara Kliewer |Nirmala Gonsalves |Evan S. Dellon |David A. Katzka

Background Empirical elimination diets are effective for achieving histological remission in eosinophilic oesophagitis, but randomised trials comparing diet therapies are lacking. We aimed to compare a six-food elimination diet (6FED) with a one-food elimination diet (1FED) for the treatment of adults with eosinophilic oesophagitis. Methods We conducted a multicentre, randomised, open-label trial across ten sites of the Consortium of Eosinophilic Gastrointestinal Disease Researchers in the USA.

Feb 3, 2023 | jacionline.org | Ikuo Hirano |Marc E. Rothenberg |Evan S. Dellon |Margaret Collins

Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and comorbid disease at baseline: from Parts A and B of LIBERTY-EoE-TREET

Feb 3, 2023 | jacionline.org | Marc E. Rothenberg |Jonathan M. Spergel |Evan S. Dellon |Larry Borish

Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease of the esophagus. Dupilumab, a fully human mAb, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation. In phase 3 LIBERTY-EoE-TREET (NCT03633617) dupilumab improved histologic, symptomatic, and endoscopic aspects of EoE and was well tolerated.